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Abstract. Interferon-β (IFN-β) has been used clinically 
for malignant glioma growth inhibition. Recently IFN-β is 
re-evaluated for its sensitization mechanism to the chemo-
therapeutic agent temozolomide, because angiogenesis is 
essential for malignant glioma growth. In this study, we 
investigated  new mechanisms of inhibition of glioma angio-
genesis by IFN-β. Three malignant glioma cell lines, U87, 
TK2 and Becker, were used for in vitro study. The effect of 
IFN-β for these cell lines were evaluated by means of prolif-
eration (MTT assay), conditioned medium induced HUVEC 
migration, VEGF and interferon inducible protein 10 (IP10, 
angiogenesis inhibitor) expression by RT-PCR and western 
blot analysis. SCID mouse U87 subcutaneous model and U87 
implant cranial window model were used for in vivo study. 
The effect of IFN-β with the models was evaluated by means 
of tumor growth, tumor tissue expression for VEGF and IP10, 
tumor tissue CD31 positive vessel densities, apoptosis and 
tumor microcirculation (blood velocity, interaction between 
leukocytes and endothelial cells). In vitro, IFN-β upregu-
lated IP10 expression and downregulated VEGF expression 
time- (4-48 h) and dose- (10-5,000 U/ml) dependently. At 
the same dose, glioma cell-induced HUVEC migration was 
inhibited, but cell proliferation was not affected. IFN-β local 
and systemic injection at 105 U and at 5x105 U/day, for 15 days 
inhibited U87 subcutaneous growth significantly. In the tumor 
tissues, VEGF expression and vessel densities were downreg-
ulated, but IP10 expression and apoptosis index upregulated. 
In addition, IFN-β local injection increased collagen fiber 
deposition in the tumor tissues. IFN-β 5x105 U/day, s.c. injec-
tion for 7 days reversed the decreased leukocyte adhesion to 
endothelial cells, but did not affect blood velocity and vessel 
images. One of the important roles of IFN-β for malignant 
glioma growth inhibition was anti-angiogenesis by directly 
inhibiting angiogenesis through downregulation of VEGF 
and upregulation of IP-10 and indirectly changing the tumor 
microcirculation and regulating the interstitial pressure.
Introduction
Interferons (IFNs) are a family of natural glycoproteins that 
consist of IFN-α, -β and -γ. The antiviral activity of IFNs 
led to their discovery, but later data revealed that they also 
control cell growth and differentiation, inhibit expression of 
oncogenes, and activate T lymphocytes, natural killer cells 
and macrophages. Therefore, the efficacy of IFN therapy for 
various malignancies, including malignant gliomas (1), has 
been investigated for many years.
Recently anti-glioma action of IFN-β has been re-evaluated. 
IFN-β markedly enhanced sensitivity to temozolomide (TMZ) 
via downregulation of MGMT transcription (2,3). The results 
of the study suggest that compared to TMZ-based chemo-
therapy plus radiotherapy, chemotherapy with IFN-β and TMZ 
and concomitant radiotherapy further improve the clinical 
outcomes of patients with malignant gliomas. A multicenter 
phase I clinical trial established that therapy with IFN-β and 
TMZ is safe, well tolerated, and prolongs survival of patients 
with glioblastoma (4,5). Taken together, IFN-β increased the 
therapeutic efficiency of TMZ in cases of newly diagnosed 
primary glioblastoma, particularly in patients with the 
unmethylated MGMT promoter (6). A prospective random-
ized control trial to compare the clinical outcomes of newly 
diagnosed glioblastoma patients treated with TMZ alone or 
with TMZ and IFN-β combination therapy is ongoing.
Because glioblastoma is one of the most richly neovascu-
larized solid tumors in terms of vasoproliferation, endothelial 
cell hyperplasia, and endothelial cell cytology (7), antiangio-
genic approach may be especially suitable for the treatment 
of malignant gliomas (8). Recent large clinical study clearly 
demonstrated the effectiveness of anti-VEGF antibody (beva-
cizumab) for malignant glioma (9,10). Antiangiogenic activity 
of IFN-β has been reported previously, IFN-β inhibits some 
growth factors (bFGF, interleukin 8) (11,12) and gelatinase (13) 
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transcription and/or protein production. In this study, we 
investigated the antiangiogenic effect of IFN-β for malignant 
gliomas in vitro and in vivo, especially about VEGF produc-
tion, angiogenic stimuli and inhibitor balance, and tumor 
microcirculation that are not previously proven mechanisms 
as antiangiogenic actions of IFN-β.
Materials and methods
Human glioma cell lines and culture conditions. The human 
glioma cell line U-87 MG was obtained from the American 
Type Culture Collection (Rockville, MD). The human glioma 
cell line TK2 was established from glioblastoma at the 
Department of Neurosurgery, University of Tsukuba. The 
human glioma cell line, Becker, was a generous gift. Cells 
were maintained in MEM supplemented with 10% FCS in a 
humidified atmosphere containing 5% CO2 at 37˚C.
Human umbilical cord vein endothelial cells (HUVECs) 
harvested from umbilical cords were a generous gift of 
Dr Okuda (University of Tsukuba). HUVECs were maintained 
with collagen coated flasks (Iwaki Glass, Tokyo, Japan) in 
E300 medium (Kyokuto, Tokyo, Japan) which are designed 
for HUVEC culture containing 2% fetal calf serum, heparin, 
aFGF and EGF.
Reagents. Human IFN-β was a gift from Toray Industries, Inc. 
(Tokyo, Japan).
Cell proliferation assay (MTT assay). Cell proliferation assays 
were performed using the CellTiter 96™ Aqueous 
Non-Radioactive Proliferation Assay (Promega Corp., 
Madison, wI) as described previously (14). This assay measures 
the reduction of a tetrazolium compound (3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium), by living cells to a formazan product. Briefly, 
the glioma cells, 1x105/ml in DMEM with 10% FCS, were 
plated in 96-well plates (Becton Dickinston, Lincoln Park, NJ) 
at 5,000 cells. After 24-h incubation, the various doses of 
IFN-β (10 to 5,000 U/ml) were added to the wells. The cells 
were incubated for 48, 96, 144 h. At the end of incubation 
period, to the microplate wells were added 20 µl of a freshly 
prepared combined tetrazolium compound and an electron 
coupling reagent (phenazine methosulfate) solution, then incu-
bated for 2 h at 37˚C, and the optical density at 490 nm was 
read on an automatic microplate reader (Model 550, Bio-Rad). 
The experiment was repeated at least three times in triplicate 
wells for each concentration of IFN-β.
Western blot analysis. The tissues and the cell pellets were 
homogenized with a ultrasonic homogenizer on ice in 1 ml 
of extraction buffer [25 mM Tris, 100 mM NaCl, 20 mM 
NH4HCO3, pH 7.5, protease inhibitor cocktail; Complete 
Mini (Roche) one tablet] per 100 mg wet weight of tissue 
and the protein lysates were obtained after centrifugation at 
50,000 x g for 30 min at 4˚C. Lysates containing 50 µg of 
total protein, as estimated by the method of Bradford using 
bovine serum albumin as a standard, were separated on 
12% SDS-polyacrylamide gel, electroblotted onto 0.2 µm 
nitrocellulose membrane (Bio-Rad) and were immunoassayed 
with rabbit polyclonal anti-VEGF antibody (A-20, 100 µg/ml, 
Santa Cruz Biotechnology, Santa Cruz, CA) at the dilution 
of 1:200 and mouse monoclonal anti-human IP-10 antibody 
(500 µg/ml, Dako, Glostrup, Denmark) at the dilution of 1:100. 
The immunocomplexes formed were visualized with alkaline 
phosphatase-conjugated anti-rabbit or anti-mouse immuno-
globulin G (IgG) using ECL western blot analysis system 
(Amersham Pharmacia Biotech).
U87 SCID mouse subcutaneous model. After the implanta-
tion of 1x105 U87 cells in the flank of 6 weeks old male 
SCID mouse (Clea Japan), U87 tumor tissue fragments were 
removed and then re-implanted into another SCID mouse. 
Harvested tumor fragments, 1 mm3 in size, were implanted 
into the flank of 17 SCDI mice. The animals were divided 
into 3 groups randomly; 5 control group, 5 IFN-β low dose 
group, 7 IFN-β high dose group. IFN-β treatment was started 
at day 7 after the implantation when the subcutaneous tumor 
reached 5 mm in size. IFN-β was locally injected adjacent 
to the tumor 1x105 U (low dose group) and 5x105 U (high 
dose group) once daily for 15 days. Size of the subcutaneous 
tumor was measured by caliper. At 15 days after the treat-
ment, the tumor tissue was removed. A part of the tissue was 
immediately fixed in 10% phosphate-buffered formalin for 
48 h, paraffin-embedded, and used for routine pathological 
diagnosis and immunohistochemistry. The other part of the 
tissue was immediately frozen with liquid nitrogen and stored 
at -70˚C. Two mice of the 7 IFN-β high dose group survived 
for next 20 days without any treatment and tumor volume was 
measured.
Similar set of the U87 subcutaneous tumor experiments 
were repeated with IFN-β systemic (intraperitoneal) injec-
tion instead of local injection. Fifteen mice were divided into 
3 groups; 5 control, 5 IFN-β low dose and 5 IFN-β high dose. 
This systemic injection experiment was only used to measure 
the tumor volume between three groups.
RNA isolation and reverse transcription polymerase chain 
reaction (RT-PCR). Total RNA was extracted from IFN-β 
treated and control frozen tumor tissues (4 controls, 4 IFN-β low 
dose, 4 IFN-β high dose) and glioma cell lines treated with 
IFN-β using RNeasy mini kit (Qiagen GmbH, Germany). 
Quantitative RT-PCR for IP10 and VEGF mRNA in glioma 
cells and glioma tissues has been described previously (15). we 
performed RT-PCR with the GeneAmp™ RNA PCR Kit 
(Perkin-Elmer Cetus, Norwalk, CT). Briefly, 1 µg of total RNA 
was reverse transcribed by MuLV reverse transcriptase in the 
presence of random hexamer, followed by indicated cycles of 
PCR reaction (95˚C for 1 min, 55˚C for 1 min and 72˚C for 
1 min) in the presence of 2 µM IP10 specific primers (32 cycles), 
VEGF specific primers (28 cycles), or the β-actin specific 
primers (16 cycles) as a control. The IP10 primers were designed, 
the reverse primer (5'-GATTCAGACATCTCTTCTCACCC-3') 
is complementary to positions 295-275, and the forward primer 
(5'-TGACTCTAAGTGGCATTCAAGG-3') corresponds to 
positions 107-128 (16). The VEGF primers included the reverse 
primer (5'-CCTGGTGAGAGATCTGGTTC-3') spanning 
bases 861-842 and the forward primer (5'-TCGGGCCTCCGA 
AACCATGA-3') spanning bases 141-160. The β-actin primers 
included the reverse primer (5'-GGAGTTGAAGGTAGTTTC 
GTG-3') spanning bases 2429-2409 and the forward primer 
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(5'-CGGGAAATCGTGCGTGACAT-3') spanning bases 
2107-2126. The predicted sizes of the amplified IP10 and 
β-actin DNA products were 188 and 214 bp, respectively. The 
VEGF primers were chosen because they amplified exons 3 
to 8 and allowed for distinguishing between the different 
VEGF splicing variants. PCR products of 516 and 648 bp 
corresponded with VEGF121 and VEGF165, respectively. The 
quantification of these RT-PCR product levels was performed 
on a Macintosh computer using the public domain NIH Image 
program (developed at the US National Institute of Health).
Antibodies and immunohistochemistry. The Dako LSAB Kit 
for mouse and rabbit primary antibody (Dako) was used. Tissue 
sections were deparaffined and incubated with 10% normal 
goat serum in PBS for 20 min. The sections were then incu-
bated with a polyclonal anti-VEGF antibody, A-20 (Santa Cruz 
Biotechnology) at a dilution of 1/100 (1 µg/ml IgG) in PBS 
overnight at 4˚C, and a monoclonal anti-mouse CD31 antibody 
(BD Pharmingen) at a dilution of 1/200 in PBS for 60 min at 
room temperature. Chromatographically purified mouse IgG 
and rabbit IgG (Dako) at the same IgG concentration were 
used as negative controls. Sections were incubated with biotin-
conjugated goat anti-mouse or anti-rabbit immunogloblin for 
10 min, followed by washing in PBS for 10 min. The sections 
were then incubated with peroxidase conjugated streptavidin 
solution for 5 min, followed by washing in PBS for 5 min. 
Sections were then stained with freshly prepared amino-
ethylcarbazole solution for 10 min, followed by washing for 
5 min in tap water. The sections were then counterstained with 
hematoxylin and mounted with aqueous mounting media. The 
intracellular VEGF immunostaining was assessed separately 
for tumor and endothelial cells using a semiquantitative scale 
(-, not detected; +, moderate; ++, strong).
Tumor vascular density. Vascular density was scored using 
the vasoproliferative component of the MAGS (microscopic 
angiogenesis grading system) that has been used to quantify 
angiogenesis in a variety of tumors (17). The number of 
vessels at 200X field (1.0 mm2) was measured in microvessel 
‘hot spots’ (i.e., microscopic areas containing the most dense 
collections of microvessels, as initially identified under low 
power magnification) with the use of an Olympus microscope, 
AHBT3 (Olympus, Tokyo, Japan) on CD31 stained tissue 
sections. Vascular density was defined by averaging the 
number of vessels in the three most vascularised areas.
Histochemical detection of apoptotic cells and determination 
of apoptotic index. Apoptotic cells were visualized using the 
ApopTag in situ detection kit (Oncor, Gaithersburg, MD) as 
described previously (15). The staining procedures were modi-
fied based on the manufacturer's instructions. Briefly, after 
deparaffinization and rehydration, the tissues were digested 
with proteinase K (20 µg/ml in PBS; wako, Osaka, Japan) for 
20 min at room temperature and washed. Slides were then put 
into 3% H2O2 for 5 min and washed with PBS. After adding 
the equilibration buffer for 10 min. TdT enzyme was pipetted 
onto the sections, which were then incubated at 37˚C for 1 h. 
The reaction was stopped by putting sections in stop/wash 
buffer. After washing, anti-digoxigenin-peroxidase was added 
to the slides. Slides were washed, stained with diaminobenzi-
dine (DAKO) substrate, and counterstained with hematoxylin. 
A specimen known to be positive for apoptotic cells was used 
as positive control for subsequent staining. Substitution of TdT 
with distilled water was used as a negative control. The apop-
totic index was expressed as the ratio of positively staining 
tumor cells to all tumor cells, given as a percentage for each 
case. At least five representative areas without necrosis in a 
section were selected by light microscopy using 40- to 200-fold 
magnification. A minimum of 3,000 cells was counted under 
a 400-fold magnification. Positively staining tumor cells with 
the morphological characteristics of apoptosis were identified 
using standard criteria, including chromatin condensation, 
nucleolar disintegration, and formation of crescentic caps of 
condensed chromatin at the nuclear periphery.
Glioma conditioned medium induction of HUVEC migration. 
Glioma cells (1x105) were plated into a 6-well plate. After 
incubation for 24 h in MEM with 10% FCS, the medium 
was changed to MCDB107 with 0.5% FCS containing 
various concentrations of IFN-β. After 48 h incubation, the 
conditioned medium was harvested and the concentration of 
VEGF in glioma conditioned medium was measured using 
Quantikine™ Human VEGF Immunoassay (R&D Systems, 
Minneapolis, MN). Endothelial cell migration was evaluated 
by 24-well modified Boyden chamber (Coster, Cambridge, 
MA) as described previously. The chamber contains 
Nucleopore polycarbonate membranes (8-µm pore size) that 
had been soaked overnight in 0.1% gelatin in 0.1% acetic acid. 
A total of 100 µl of HUVECs, 2x106 cells/ml in MCDB107 
with 0.5% FBS, was plated in upper well and 600 µl of 
collected conditioned medium was added to lower wells. The 
assembly was incubated for 6 h. The membrane was removed, 
fixed in methanol, stained with hematoxylin and the cells in 
upper surface were gently wiped with cotton swab. The insert 
was mounted on glass slide. The number of migrated cells was 
counted from at random five fields using x25 magnification. 
Data were expressed as cells per field. One field corresponded 
to 0.09 mm2 (width, 309 µm x height, 291 µm) of the membrane 
area. The experiment was repeated two times in quadruplicate 
for each concentration.
SCID mouse U87 implant cranial window model and quan-
titation of intravital tumor microcirculation. U87 tumor 
tissue fragment (1 mm3) was implanted on the surface of 
the SCID mouse cranial window (n=3). IFN-β was injected 
intraperitoneally for 7 days, and then the cranial window was 
evaluated for tumor microcirculation. Three series of experi-
mental studies to visualize blood flow dynamics of the tumor 
microcirculation and to quantify their microhemodynamic 
parameters were performed (18).
First, by labeling plasma component, the tumor microvas-
culature was visualized and mapped to obtain information 
on vascular architecture and dimensions of microvessels. To 
enhance the contrast of microvessel images against a dark 
background, a solution of FITC-labeled dextran (FITC-Dx, 
Mw 150,000; Sigma, St. Louis, MO) was intravenously 
injected (20 mg/ml, 2 ml/kg). This permitted bright fluores-
cence images of the vascular lumen, and enabled mapping 
of the vascular architecture and accurate measurements of 
luminal diameter. The diameter of microvessels was measured 
TAKANO et al:  INTERFERON-β INHIBITS GLIOMA ANGIOGENESIS1840
carefully with a vernier caliper on the standstill frame of 
the video-recorded images by playback of a high quality 
video-cassette recorder (Model BR-S605B). Their average 
values were calculated from five measurements in each vessel.
Secondary, to visualize the flow behavior of erythrocytes 
in vivo and to measure their velocities, a part of erythrocytes 
was labeled fluorescently and injected intravenously. The arte-
rial blood (0.2 ml) of a donor mouse was collected from a tail 
vein into a 1.5 ml test tube containing heparin (100 units) for 
anticoagulation. The erythrocytes were separated from the 
plasma by centrifugation and were washed twice with pysio-
logical saline solution. These erythrocytes were then incubated 
at room temperature with a phosphate-buffered saline (PBS) 
solution, adjusted to pH 7.8, containing 1 mg/ml fluorescein 
isothiocyanate (FITC). After 60 min of incubation, the labeled 
cells were washed twice with a saline solution containing 
1% bovine serum albumin to remove uncombined fluores-
cent dyes. The final volume percent of the labeled cells was 
adjusted to 50% by adding an isotonic saline solution. These 
suspensions were injected intravenously through a tail vein. 
The erythrocyte velocity was calculated by a frame-by-frame 
analysis and averaged for at least 10 measurements.
Thirdly, to analyze the leukocyte behavior and the leuko-
cyte-endothelium interaction, leukocytes were also labeled 
fluorscently. A working solution of rhodamine 6G (Sigma) was 
prepared by dissolving 10 mg of the dye in 40 ml of physi-
ological saline. This solution was diluted with saline until a 
final concentration of 50 µg/ml. The optimal concetration of 
the dye for imaging leukocytes was determined from several 
preliminary experiments. Each solution was freshly prepared 
on the day of the experiment and filtered through a 0.22 µm 
filter before each experiment. Leukocytes were found to be 
visualized by injecting a small bolus of 2 ml/kg of the solu-
tion intravenously. Arolling leukocyte was defined as one that 
marginates along the vessel wall and is clearly dissociated 
from the bulk of the blood flow. An adhering leukocyte was 
defined as one that stays stationary during at least 15 sec of the 
30-sec observation period (19).
Statistical analyses. Vascular density, MIB-1 positivity, apop-
tosis index, tumor volumes, densitometric value of VEGF, 
IP10 and β-actin, and the parameter of tumor microcirculation 
(diameter, velocity, number of leukocyte) were expressed as 
mean ± SD. Statistically significant differences between the 
groups were determined using a one-way analysis of variance 
and the Tukey's test. All p-values are two-sided; values are 
considered statistically significant for p<0.05.
Results
Antiangiogenic activity of IFN-β in vitro. RT-PCR analysis 
demonstrated IFN-β upregulated IP10 mRNA expression 
time- (4-48 h) and dose- (10-500 U/ml) dependently, but not 
VEGF mRNA expression (Fig. 1). However, VEGF protein 
concentration and secretion in the conditioned medium was 
decreased time- and dose-dependently by IFN-β treatment 
(Fig. 2). IP10 protein in cell extracts was increased time- and 
dose-dependently with IFN-β treatment (Fig. 3). Increased 
VEGF and decreased IP10 protein expression of glioma cells 
treated with IFN-β at 100 U/ml for 48 h resulted in the inhibi-
tion of HUVECs migration (Fig. 4A). By contrast, glioma cell 
proliferation was not affected by IFN-β treatment for 48 h at 
the dose ranging from 10 to 5,000 U/ml (Fig. 4B).
IFN-β inhibition of glioma growth in subcutaneous tumor. 
IFN-β local injection as well as systemic injection for 
15 days significantly inhibited U87 subcutaneous growth 
(Fig. 5). VEGF protein expression of U87 tumor tissues was 
decreased dramatically in the IFN-β high dose treatment, 
while IP10 protein expression increased (Fig. 6A). RT-PCR 
analysis demonstrated that IP10 mRNA expression of the 
tumor tissues was not detected in any of control group. 
Upregulation of IP10 mRNA expression of the tumor tissues 
was observed in 2 of 4 IFN-β low dose group and all 4 in 
IFN-β high dose group. VEGF mRNA expression of the 
tumor tissues was not affected by RT-PCR analysis (Fig. 6B). 
Immunohistochemistry clearly demonstrated high VEGF 
expression in the control tumor tissues and decreased VEGF 
expression in the IFN treated tumor tissues (Fig. 7). VEGF 
expression was strong in 5 of 5 control group and in none of 
IFN-β high and low dose group. CD31 positive vessel densities 
were significantly decreased both in the IFN-β low and high 
treated groups compared to control group (Table I). In IFN-β 
high treated group, MIB-1 positivities were significantly low 
and apoptosis indices were significantly high compared to 
the control animals (Table I). The growth inhibitory effect of 
IFN-β was reversible because the tumor did re-start to grow 
after the discontinuation of the IFN-β treatment at similar 
degree to control tumors (Fig. 5A). In addition, IFN-β treat-
ment increased collagen fiber deposition in the tumor tissues, 
Figure 1. RT-PCR analysis for the transcripts of IP10, VEGF and β-actin in glioma cells, (A) TK2 and (B) Becker. (A) No IP10 mRNA expression in the 
control, but IFN-β 100 U/ml induced IP10 expression time-dependently between 4- and 48-h treatment. (B) No IP10 mRNA expression in the control, but 
IFN-β treatment for 6 h induced IP10 expression dose-dependently between 10 and 500 U/ml of IFN-β.
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which was demonstrated by Masson's Trichrome stain 
(Fig. 7C and D). The increase was not observed in the group 
of systemic IFN-β treatment.
IFN-β inhibition of glioma microcirculation. with the cranial 
window model, 7 days after the U87 fragment implantation, 
tortuous vessels grew around the fragment where red blood 
cell velocity and the degree of leukocyte adhesion and rolling 
significantly decreased compared to those of the normal 
cortical vein at the diameter of 20-80 µm. IFN-β systemic 
treatment for 7 days dramatically reversed the decreased 
leukocyte adhesion and rolling in the U87 glioma graft, while 
tortuous vessel morphology and red blood cell velocity were 
not unchanged (Table II).
Discussion
Our study clearly demonstrated that IFN-β inhibited glioma 
angiogenesis in three different aspects, in vitro, subcutaneous 
tumor, and intracerebral tumor microcirculation. The local 
and systemic administration of IFN-β to SCID mouse bearing 
human glioblastoma cells decreased expression of VEGF, 
induced expression of IP10, reduced vascular density and 
inhibited reversible tumor growth. Also the systemic admin-
istration of IFN-β significantly inhibited glioma growth and 
reversed the microcirculation of the glioma tissues to that of 
the non-tumor brain tissue, suggesting the anti-proliferative 
effect is not due to only high local concentrations of the 
protein. Among these manifestations, simultaneous action 
with upregulation of VFGF and downregulation of IP10 is 
unique. Because angiogenesis is influenced by the balance 
between stimulatory and inhibitory molecules released by the 
tumor and its microenvironment, any decrease in a stimula-
tory molecule or an increase in an inhibitory molecule should 
reduce the level of neovascularization within the tumor.
Antiangiogenic action of IFN-β. Clinical data concluded 
that the systemic chronic administration of IFN-α or IFN-β 
accelerate the regression of richly vascularized tumors, 
e.g., life-threatening hemangiomas of infancy (20), hemangio-
Table I. U87 tumor pathology 25 days after interferon-β treatment.
 Tumor volume MIB-1 Apoptosis Vessel density
 (mm3) (%) index (%) (no./mm2)
Control 12,371.4±3,195.3 38.2±3.9 0.20±0.001 89.0±11.4
IFN-β low 1,523.8±1,354.4b 31.4±6.4 0.56±0.104 54.0±11.1b
IFN-β high 769.0±339.0b 21.8±2.7a 1.00±0.024b 78.3±8.8b
ap<0.05, bp<0.01 compared to control.
Figure 2. VEGF protein expression of glioma cells. (A) western blot analysis showed dose-dependent inhibition of Becker secretion of VEGF by IFN-β 
treatment. (B) VEGF concentration of conditioned medium measured by ELISA was decreased time and dose dependently by IFN-β. The same samples 
were used for western blot analysis after 50X concentration.
Figure 3. IP10 protein expression of glioma cells. western blot analysis showed 
time- (TK2) and dose- (Becker) dependent increase of IP10 expression.
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endotheliomas (21), hemangiopericytoma (22) and Kaposi's 
sarcomas (23). The mechanisms responsible for this remark-
able clinical outcome remained unclear. IFN-β can inhibit 
angiogenesis by several mechanisms.
In vitro, IFN-β inhibits endothelial cell proliferation (11), 
endothelial cell migration (24), downregulation of transcrip-
tion and production of bFGF protein (11), interleukin 8 (25) 
and collagenase type IV (13), all of which are involved in the 
angiogenic response. In addition, our data demonstrate IFN-β 
inhibits production of VEGF protein, although the effects is 
marginal, and induces production of IP10, endogenous angio-
genesis inhibitor, resulting in inhibition of HUVEC migration 
induced by glioma conditioned medium.
However, the antiangiogenic mechanism of IFN-β for 
malignant gliomas has not been investigated comprehensively. 
Boethius et al (26) reported that systemic administration of 
IFN-α to patients with glioblastoma multiforme induced 
marked changes in the tumor vasculature, which supports 
the notion that IFN-α may have an effect on tumor vessels. 
we demonstrated that IFN-β inhibits glioma cell induced 
endothelial cell migration, VEGF secretion in the glioma cell 
conditioned medium, and VEGF expression and vessel densi-
ties in the glioma tissues. IFN-β is superior to IFN-α in terms 
of anti-angiogenic effects (27). The above strongly suggests 
that the in vivo antitumor effect of IFN-β in malignant gliomas 
may be mediated, at least in part, via the angiogenesis inhibi-
tion rather than the antiproliferative activity on tumor cells. 
Hong et al (28) demonstrated the level of VEGF and bFGF 
expression of U87 cells was not influenced by IFN-β treat-
ment at concentrations from 10-500 IU/ml for 24 and 72 h. 
They measured the expression of cell extract and we measured 
secreted protein of VEGF.
IFN-β inhibits VEGF secretion. we reported that IFN-β 
treatment inhibited glioma cell VEGF secretion in vitro and 
glioma angiogenesis with downregulation of VEGF in glioma 
tissue. The investigations concerning to relationship of VEGF 
inhibition and IFN-β are very limited. VEGF promotes phos-
phorylation-dependent ubiquitination and degradation of IFN 
receptor and ensuing attenuation of IFN-α/β signaling; these 
processes appear to be required for efficient angiogenesis (29). 
In another report, the antitumor effect of IFN-β was offset 
by the tumor-progressive character of endothelial progenitor 
cells (EPCs) and the tumor growth, and the vascular density 
of tumor tissues increased by the co-implanted EPCs were 
decreased upon IFN-β treatment. In addition, overall expres-
sion levels of VEGF in tumor tissues that were decreased 
upon IFN-β treatment (30).
Recent clinical studies indicate that anti-VEGF agents 
are important for the treatment of angiogenesis-dependent 
diseases. The approaches used today are mainly based on the 
development and administration of functional recombinant 
protein antagonists that either neutralize the extracellular 
VEGF function or block VEGF signaling in target cells. The 
disadvantages of current therapeutic strategies are many, 
Figure 4. Endothelial cell migration and tumor proliferation. (A) HUVEC migration induced by glioma cell (Becker) conditioned medium. IFN-β at 100 U/ml 
significantly inhibited HUVEC migration. (B) IFN-β at the dose range 10-5,000 U/ml for 48 h did not inhibit glioma cell (Becker) proliferation measured 
by MTT assay.
Figure 5. IFN-β inhibition of U87 glioma growth in subcutaneous tumors. 
Intra tumoral injection of IFN-β low and high dose inhibited U87 sub-
cutaneous tumor growth. Inhibition of tumor growth re-started after 
discontinuation of IFN-β (after 26th day of tumor implantation).
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including difficulties in manufacturing active recombinant 
protein, high-dose requirements, high costs for manufactures 
and consumers, and the probable need for lifetime treatment of 
the patient. A novel anti-VEGF strategy by blocking its secre-
tion in tumor cells is reported by retaining a VEGF binding 
protein in the cell (31), by inhibiting VEGF promoter activity 
Table II. U87 tumor microcirculation with interferon-beta treatment.
 Vessel Red blood cell Vessel Leukocyte
 diameter velocity diameter adhesion, rolling
 (µm) (µm/sec) (µm) (no./600 sec)
No tumor 23.9±10.5 475.6±175.3 45.6±34.7 112.1±80.5
U87 tumor 19.8±8.9 248.0±91.2 35.0±21.0 27.9±14.7
U87 tumor, IFN 20.0±0.2 277.2±8.7 66.0±15.2 306.8±131.5a
ap<0.05 compared to no treatment.
Figure 6. VEGF and IP10 expression in the IFN-β treated and control tumor tissues. (A) western blot analysis shows IFN-β high dose treatment inhibited 
VEGF protein expression and induced IP10 protein expression in the tumor tissues. (B) RT-PCR analysis shows IFN-β induction of IP10 mRNA expression 
in 2 of 4 low dose group and in all of the high dose group.
Figure 7. (A and B) VEGF immunohistochemistry and (C and D) Masson's Trichrome stain of (A and C) control and (B and D) IFN-β high dose group. Note 
marked decreased expression of VEGF and increased collagen fiber deposition in the treated group. Original magnification, x100.
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on neuroendocrine tumor cell lines (32), by a PI3 kinase 
inhibitor in melanoma (33) and by IFN-α in melanoma cell 
line (34). PI3 kinase activation may occur via loss of phos-
phatase and tensin homolog (PTEN) that is closely related to 
IFN-β sensitivity in glioma (35). Taken together, IFN-β treat-
ment appears to be one of novel strategies of anti-angiogenesis 
on glioma by preventing VEGF secretion.
IP10 antiangiogenic action. IFN-β upregulates IP10 from 
a number of cells, including keratinocytes, fibroblasts, 
endothelial cells, mononuclear phagocytes and cancer cells. 
IFN-β may shift the biological balance of ELR+ (IL-8) and 
ELR-CXC (IP10) chemokines, leading to reduced net angio-
genic activity (36). IP10 is a potent inhibitor of not only ELR+ 
CXC chemokine (IL-8) but also the unrelated angiogenic 
factors bFGF and VEGF (36).
The production of IP10 from adenocarcinoma and squa-
mous carcinoma tumors was inversely correlated with their 
growth. SCID mouse bearing tumors were given intratumor 
injection of recombinant human IP10. IP10 treatment resulted 
in a >40% reduction in tumor size and mass, respectively. 
The mechanism of growth inhibition by intratumor admin-
istration of IP10 was found to be correlated with a reduction 
in primary tumor-derived angiogenic activity and neovascu-
lature (37). IP10 protein expression was inversely correlated 
with vascular density and clinical behavior in endometrial 
cancer (38). we demonstrated IFN-β treatment shifted the 
balance of VEGF/IP-10 into angiostatic state in glioma cells 
and tissue. Interestingly, IP-10 has been identified as a major 
biological marker mediating cancer severity and may be 
utilized as a prognostic indicator for various cancers (39). 
IP-10 shows potential as a biological response marker of 
IFN-β in glioma.
IFN-β affects tumor microcirculation in gliomas. Yuan et al 
(40) and Foltz et al (19) reported the intravital microscopic 
analysis of malignant gliomas transplanted into a cranial 
window preparation. Although cranial window model to visu-
alize tumor microcirculation is not a new method, this method 
is superior to the present MRI based evaluation of tumor 
vasculature, such as perfusion MRI (41) and vessel architec-
ture imaging (42). Intravital analysis with the cranial window 
model can provide us information of the tumor microcircu-
lation, such as leukocyte adhesion to vessel wall in addition 
to vessel architecture. Malignant glioma caused decreased 
number of leukocyte adhesion to endothelial cells, which is 
a key factor in the tumor microcirculation. we demonstrated 
that IFN-β influenced the glioma microcirculation with 
reversal of the inhibition of leukocyte adhesion. IFN-β inhibits 
activated leukocyte migration through human brain microvas-
cular endothelial cell monolayer (43). Implantation of IFN-β 
producing cells upregulated the adhesion molecules, ICAM-1 
and VCAM-1 (27). TNF-α by co-treatment with IFN-β 
increased soluble VCAM-1 in human cerebral endothelial 
cells (44). VEGF antagonist, such as soluble Flt1 (soluble form 
of VEGF receptor) increases ICAM1, VCAM1 and leukocyte 
adhesion in endothelial cells (45). Our data suggest IFN-β 
increased ICAM1 and VCAM1 directly or indirectly through 
inhibition of VEGF production with glioma cells, resulting 
reversal of leukocyte adhesion.
Taken together, the reversal effect of IFN-β on the tumor 
microcirculation that is considered as a concept for vascular 
normalization (46), could be one of the mechanisms by which 
IFN-β treatment exerts antiangiogenic effects in malignant 
glioma.
IFN-β affects matrix reaction. Matrix modifications were 
characterized on histological sections stained with Masson's 
Trichrome stain. Collagen deposition or structure of IFN-β 
treated animals appeared to be thicker than in the non-treated 
ones. The collagen deposition was prominently observed 
with local injection of IFN-β, but not with systemic treat-
ment. Combined with the similar increase of collagen fiber 
in the stromal tissue surrounding the IFN-producing tumor 
cells (27), high concentration of IFN-β in the tissues is needed 
for this thicker collagen deposition. Thicker collagen deposi-
tion may increase the interstitial pressure in the tumor and 
decrease diffusion of angiogenic molecules, e.g., VEGF, to the 
endothelial cells, resulting in inhibition of angiogenesis (47). 
However IFNs are species specific. Our studies on the effect 
of the IFNs concerning the host microenvironment (immune, 
endothelial cells and extracellular matrix) have some limita-
tions.
In conclusion, one of the important roles of IFN-β for 
malignant glioma growth inhibition was anti-angiogenesis 
by directly inhibiting angiogenesis through downregulation 
of VEGF and upregulation of IP-10 and indirectly changing 
the tumor microcirculation and regulating the interstitial pres-
sure. At present, the clinical effectiveness of IFN-β for human 
malignant gliomas is limited. Several published studies have 
shown that anti-angiogenic agents act synergistically with 
chemotherapy or radiation therapy. Also the growth inhibitory 
effect was reversible and non-toxic even with high dose of 
IFN-β in our study, suggesting combination therapy with IFN-β 
and chemotherapy or radiation therapy for long-term usage will 
overcome many of the limitations of individual treatment.
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